Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Helsinki University Central Hospital.
Recruitment status was  Recruiting
Helsinki University
Academy of Finland
Information provided by:
Helsinki University Central Hospital Identifier:
First received: January 26, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted

The safety and preliminary efficacy of the addition of an aqueous curcumin-cyclodextrin complex (CDC) solution to graft perfusion solution is studied. CDC has proved safe and highly effective in preventing primary graft non-function, delayed graft function and chronic dysfunction in pre-clinical kidney transplantation animal models. The hypothesis is that addition of CDC to the graft perfusion solution will decrease the incidence of delayed graft function in human kidney transplantation subjects.

Condition Intervention Phase
End Stage Renal Failure With Renal Transplant
Device: CDC solution
Device: UW-solution
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Helsinki University Central Hospital:

Primary Outcome Measures:
  • Delayed Graft Function [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Primary non-function [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Acute rejection [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Graft function eGFR [ Time Frame: 30 days, 90 days ] [ Designated as safety issue: No ]
  • Graft Survival [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Patient Survival [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Length of stay in hospital [ Time Frame: upto 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: January 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CDC graft perfusion
Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
Device: CDC solution
2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
Other Name: Curcumin-cyclodextrin
Sham Comparator: Sham perfusion Device: UW-solution
500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
Other Name: Viaspan


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with ESRD assigned for kidney transplantation, written informed consent

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01285375

Contact: Jakob Stenman, MD, PhD +35894711

Helsinki University Central Hospital Recruiting
Helsinki, Finland, 00029-HUS
Principal Investigator: Kaija Salmela, Docent         
Sub-Investigator: Jakob Stenman, MD, PhD         
Sub-Investigator: Marko Lempinen, MD, PhD         
Sub-Investigator: Lauri Kyllönen, Docent         
Sponsors and Collaborators
Helsinki University Central Hospital
Helsinki University
Academy of Finland
Principal Investigator: Kaija Salmela, Docent Head of Kidney Transplantation Unit
  More Information

No publications provided

Responsible Party: Kaija Salmela, MD, Head of Kidney Transplantation Unit, Department of Liver and Transplantation Surgery Identifier: NCT01285375     History of Changes
Other Study ID Numbers: 236153, 236153
Study First Received: January 26, 2011
Last Updated: January 26, 2011
Health Authority: Finland: National Supervisory Authority for Welfare and Health

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses processed this record on November 20, 2014